Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children

Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐p...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 84; no. 1; pp. 197 - 203
Main Authors Allegra, Sarah, Fatiguso, Giovanna, De Francia, Silvia, Favata, Fabio, Pirro, Elisa, Carcieri, Chiara, De Nicolò, Amedeo, Cusato, Jessica, Di Perri, Giovanni, D'Avolio, Antonio
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 01.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.
AbstractList Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females ( P  < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.
Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high-performance liquid chromatography-mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high-performance liquid chromatography-mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.
Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.
Author Allegra, Sarah
D'Avolio, Antonio
Fatiguso, Giovanna
Carcieri, Chiara
Cusato, Jessica
De Francia, Silvia
Pirro, Elisa
Favata, Fabio
De Nicolò, Amedeo
Di Perri, Giovanni
AuthorAffiliation 2 Department of Biological and Clinical Sciences University of Turin, S. Luigi Gonzaga Hospital Orbassano (TO) Italy
1 Department of Medical Sciences University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital Turin Italy
AuthorAffiliation_xml – name: 1 Department of Medical Sciences University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital Turin Italy
– name: 2 Department of Biological and Clinical Sciences University of Turin, S. Luigi Gonzaga Hospital Orbassano (TO) Italy
Author_xml – sequence: 1
  givenname: Sarah
  orcidid: 0000-0003-4933-0011
  surname: Allegra
  fullname: Allegra, Sarah
  email: sarah.allegra@gmail.com
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 2
  givenname: Giovanna
  surname: Fatiguso
  fullname: Fatiguso, Giovanna
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 3
  givenname: Silvia
  surname: De Francia
  fullname: De Francia, Silvia
  organization: University of Turin, S. Luigi Gonzaga Hospital
– sequence: 4
  givenname: Fabio
  surname: Favata
  fullname: Favata, Fabio
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 5
  givenname: Elisa
  surname: Pirro
  fullname: Pirro, Elisa
  organization: University of Turin, S. Luigi Gonzaga Hospital
– sequence: 6
  givenname: Chiara
  surname: Carcieri
  fullname: Carcieri, Chiara
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 7
  givenname: Amedeo
  surname: De Nicolò
  fullname: De Nicolò, Amedeo
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 8
  givenname: Jessica
  surname: Cusato
  fullname: Cusato, Jessica
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 9
  givenname: Giovanni
  surname: Di Perri
  fullname: Di Perri, Giovanni
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
– sequence: 10
  givenname: Antonio
  orcidid: 0000-0002-1321-4126
  surname: D'Avolio
  fullname: D'Avolio, Antonio
  organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28805964$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1v3CAQhlGUqtmkPeQPVBzbgxPGGBtfIjWrfkmRmkNyRhjDLhUGB-xtt7--bHdTtVHKhRnxzPsyM6fo2AevEToHcgH5XHZqvABaEThCC6A1K0oo2TFaEErqgpUMTtBpSt8IAQo1e4lOSs4Ja-tqgeLdWkc56nmyCvdxXuEheDuFaP0KB4M3OVLBy5_BaWxCxFPUchq0n7D0PR5jGNdbJ3_YtKOt38hkN5mc_Uq6nButJht8jrBaW9dH7V-hF0a6pF8f7jN0__HD3fJzcfP105fl-5tCVRygUF0rm9yTrg0waggzPZe8bztp-pYxwzrTQm60lpwR0zRQ0Ya3TUX7kgC0QM_Q1V53nLtB9yr_OUonxmgHGbciSCv-ffF2LVZhI1hDa85oFnh7EIjhYdZpEoNNSjsnvQ5zEtCWvOFlXbGMvvnb64_J46AzcLkHVAwpRW2EspPcjSZbWyeAiN0qRV6l-L3KXPHuScWj6HPsQf27dXr7f1BcL2_3Fb8A5zuv-Q
CitedBy_id crossref_primary_10_1002_bmc_5356
crossref_primary_10_1097_MPH_0000000000002898
crossref_primary_10_1002_prm2_12086
crossref_primary_10_1002_prp2_665
crossref_primary_10_1097_FTD_0000000000000952
crossref_primary_10_3897_pharmacia_70_e111511
crossref_primary_10_1002_jcph_2440
crossref_primary_10_1007_s12281_020_00402_6
crossref_primary_10_1080_17512433_2023_2274984
crossref_primary_10_1016_j_microc_2022_107241
crossref_primary_10_1016_j_jpba_2022_114659
crossref_primary_10_1515_chem_2022_0253
crossref_primary_10_3390_pharmaceutics15010266
crossref_primary_10_1002_cpdd_1049
crossref_primary_10_3389_fphar_2021_711187
crossref_primary_10_4155_bio_2023_0020
crossref_primary_10_3390_pharmaceutics13121991
crossref_primary_10_3390_jof4040115
crossref_primary_10_1007_s12281_018_0311_3
crossref_primary_10_1080_1120009X_2024_2376453
crossref_primary_10_1016_j_chroma_2021_462444
crossref_primary_10_3390_antibiotics10121542
crossref_primary_10_1128_AAC_00955_18
crossref_primary_10_1002_jcph_1422
crossref_primary_10_3390_jof8101035
crossref_primary_10_1016_j_ejps_2023_106506
crossref_primary_10_1038_s41598_019_45345_2
crossref_primary_10_1016_j_colsurfb_2018_06_037
crossref_primary_10_1007_s00228_024_03752_z
crossref_primary_10_2217_pgs_2022_0159
crossref_primary_10_1097_FTD_0000000000000980
crossref_primary_10_1097_MOP_0000000000000713
crossref_primary_10_1002_cpdd_1218
crossref_primary_10_3389_fphar_2021_755075
crossref_primary_10_1007_s40272_024_00663_5
crossref_primary_10_1080_03602532_2019_1632888
crossref_primary_10_1155_2021_5497427
crossref_primary_10_5863_1551_6776_28_3_247
crossref_primary_10_1186_s13052_024_01684_z
crossref_primary_10_3390_jof7060456
crossref_primary_10_3390_molecules27175609
crossref_primary_10_3390_ph14121239
Cites_doi 10.1016/j.ijantimicag.2014.07.013
10.1086/524669
10.1128/AAC.00884-15
10.1093/jac/dku031
10.3324/haematol.2016.152900
10.1164/rccm.2008-740ST
10.1128/AAC.05761-11
10.1038/sj.bmt.1705754
10.1128/AAC.00251-13
10.1097/FTD.0b013e3182241b2b
10.1097/FTD.0b013e31823f3516
10.1128/AAC.00626-12
10.1016/S0149-2918(03)80126-1
10.1128/AAC.01540-12
10.1046/j.1365-2125.2003.01994.x
10.1093/cid/cis437
10.1128/AAC.01807-09
10.1086/648679
10.1002/jps.22109
10.1093/jac/dkt369
10.1007/s10096-008-0543-1
10.1128/AAC.01083-10
10.1093/jac/dks285
10.1016/S1473-3099(15)70006-X
10.1093/cid/cis599
ContentType Journal Article
Copyright 2017 The British Pharmacological Society
2017 The British Pharmacological Society.
Copyright_xml – notice: 2017 The British Pharmacological Society
– notice: 2017 The British Pharmacological Society.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1111/bcp.13401
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Voriconazole therapeutic drug monitoring in paediatrics
EISSN 1365-2125
EndPage 203
ExternalDocumentID PMC5736853
28805964
10_1111_bcp_13401
BCP13401
Genre shortCommunication
Validation Study
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
5PM
ID FETCH-LOGICAL-c4811-cb9a7401e6f153f05fd8a8d9bafd955f5bf912126a850f77143789743d2011913
IEDL.DBID DR2
ISSN 0306-5251
1365-2125
IngestDate Thu Aug 21 14:14:11 EDT 2025
Fri Jul 11 12:38:19 EDT 2025
Thu Apr 03 07:00:17 EDT 2025
Thu Apr 24 22:50:14 EDT 2025
Tue Jul 01 01:59:17 EDT 2025
Wed Jan 22 16:39:54 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords triazoles
high-performance liquid chromatography
antifungals
invasive fungal infections
therapeutic drug monitoring
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2017 The British Pharmacological Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4811-cb9a7401e6f153f05fd8a8d9bafd955f5bf912126a850f77143789743d2011913
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
UNI EN ISO UNI EN ISO 9001:2008 and 13485:2012 (CE‐IVD) Certified Laboratory; Certificate No. IT‐64386. Certification for: “DESIGN, DEVELOPMENT AND APPLICATION OF DETERMINATION METHODS FOR ANTI‐INFECTIVE DRUGS. PHARMACOGENETIC ANALYSES”.
ORCID 0000-0002-1321-4126
0000-0003-4933-0011
OpenAccessLink https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13401
PMID 28805964
PQID 1928782645
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5736853
proquest_miscellaneous_1928782645
pubmed_primary_28805964
crossref_citationtrail_10_1111_bcp_13401
crossref_primary_10_1111_bcp_13401
wiley_primary_10_1111_bcp_13401_BCP13401
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2018
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: January 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 2018
Publisher John Wiley and Sons Inc
Publisher_xml – name: John Wiley and Sons Inc
References 2010; 99
2015; 59
2015; 15
2010; 54
2001
2013; 57
2008; 27
2003; 25
2014; 69
2011; 33
2011; 55
2008; 46
2016
2007; 40
2011; 4
2011; 183
2012; 34
2012; 56
2017; 102
2012; 67
2012; 55
2014; 44
2010; 50
2003; 56
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
Nomura K (e_1_2_8_3_1) 2008; 27
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
Lat A (e_1_2_8_31_1) 2011; 4
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_22_1
e_1_2_8_23_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
Shao B (e_1_2_8_30_1) 2016
e_1_2_8_13_1
e_1_2_8_14_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_10_1
e_1_2_8_11_1
e_1_2_8_12_1
References_xml – volume: 56
  start-page: 3032
  year: 2012
  end-page: 3042
  article-title: Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults
  publication-title: Antimicrob Agents Chemother
– volume: 55
  start-page: 1080
  year: 2012
  end-page: 1087
  article-title: The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial
  publication-title: Clin Infect Dis
– volume: 50
  start-page: 27
  year: 2010
  end-page: 36
  article-title: Voriconazole pharmacokinetics and pharmacodynamics in children
  publication-title: Clin Infect Dis
– volume: 34
  start-page: 77
  year: 2012
  end-page: 84
  article-title: Therapeutic drug monitoring of voriconazole in children
  publication-title: Ther Drug Monit
– volume: 27
  start-page: 1141
  year: 2008
  end-page: 1143
  article-title: Pharmacokinetic‐pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies
  publication-title: Eur J Clin Microbiol Infect Dis
– volume: 44
  start-page: 436
  year: 2014
  end-page: 442
  article-title: Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections
  publication-title: Int J Antimicrob Agents
– volume: 99
  start-page: 3291
  year: 2010
  end-page: 3301
  article-title: Review of the basic and clinical pharmacology of sulfobutylether‐beta‐cyclodextrin (SBECD)
  publication-title: J Pharm Sci
– volume: 46
  start-page: 201
  year: 2008
  end-page: 211
  article-title: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
  publication-title: Clin Infect Dis
– volume: 15
  start-page: 461
  year: 2015
  end-page: 474
  article-title: British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases
  publication-title: Lancet Infect Dis
– volume: 55
  start-page: 4782
  year: 2011
  end-page: 4788
  article-title: Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients
  publication-title: Antimicrob Agents Chemother
– volume: 69
  start-page: 1633
  year: 2014
  end-page: 1641
  article-title: Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
  publication-title: J Antimicrob Chemother
– volume: 25
  start-page: 1321
  year: 2003
  end-page: 1381
  article-title: Voriconazole
  publication-title: Clin Ther
– volume: 4
  start-page: 43
  year: 2011
  end-page: 53
  article-title: Update on the optimal use of voriconazole for invasive fungal infections
  publication-title: Infect Drug Resist
– volume: 69
  start-page: 463
  year: 2014
  end-page: 470
  article-title: Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections
  publication-title: J Antimicrob Chemother
– volume: 55
  start-page: 381
  year: 2012
  end-page: 390
  article-title: Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics‐based analysis of adult patients with invasive fungal infections
  publication-title: Clin Infect Dis
– start-page: 1
  year: 2001
  end-page: 56
– volume: 40
  start-page: 451
  year: 2007
  end-page: 456
  article-title: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
  publication-title: Bone Marrow Transplant
– volume: 59
  start-page: 5548
  year: 2015
  end-page: 5554
  article-title: study of the variable effects of proton pump inhibitors on voriconazole
  publication-title: Antimicrob Agents Chemother
– volume: 57
  start-page: 3262
  year: 2013
  end-page: 3267
  article-title: Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies
  publication-title: Antimicrob Agents Chemother
– volume: 33
  start-page: 464
  year: 2011
  end-page: 466
  article-title: Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency
  publication-title: Ther Drug Monit
– volume: 67
  start-page: 2645
  year: 2012
  end-page: 2649
  article-title: Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC‐MS
  publication-title: J Antimicrob Chemother
– volume: 54
  start-page: 3408
  year: 2010
  end-page: 3413
  article-title: Development, validation, and routine application of a high‐performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma
  publication-title: Antimicrob Agents Chemother
– volume: 56
  start-page: 4793
  year: 2012
  end-page: 4799
  article-title: Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring
  publication-title: Antimicrob Agents Chemother
– volume: 57
  start-page: 235
  year: 2013
  end-page: 240
  article-title: Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients
  publication-title: Antimicrob Agents Chemother
– volume: 56
  start-page: 17
  issue: Suppl 1
  year: 2003
  end-page: 23
  article-title: Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole
  publication-title: Br J Clin Pharmacol
– volume: 183
  start-page: 96
  year: 2011
  end-page: 128
  article-title: An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients
  publication-title: Am J Respir Crit Care Med
– start-page: 1
  year: 2016
  end-page: 9
  article-title: Effects of cytochrome P450 3A4 and non‐genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes
  publication-title: Xenobiotica
– volume: 102
  start-page: 433
  year: 2017
  end-page: 444
  article-title: ECIL‐6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients
  publication-title: Haematologica
– ident: e_1_2_8_9_1
  doi: 10.1016/j.ijantimicag.2014.07.013
– ident: e_1_2_8_16_1
  doi: 10.1086/524669
– ident: e_1_2_8_5_1
  doi: 10.1128/AAC.00884-15
– ident: e_1_2_8_8_1
  doi: 10.1093/jac/dku031
– ident: e_1_2_8_14_1
– ident: e_1_2_8_20_1
  doi: 10.3324/haematol.2016.152900
– ident: e_1_2_8_2_1
  doi: 10.1164/rccm.2008-740ST
– ident: e_1_2_8_25_1
  doi: 10.1128/AAC.05761-11
– volume: 4
  start-page: 43
  year: 2011
  ident: e_1_2_8_31_1
  article-title: Update on the optimal use of voriconazole for invasive fungal infections
  publication-title: Infect Drug Resist
– ident: e_1_2_8_18_1
  doi: 10.1038/sj.bmt.1705754
– ident: e_1_2_8_29_1
  doi: 10.1128/AAC.00251-13
– ident: e_1_2_8_12_1
  doi: 10.1097/FTD.0b013e3182241b2b
– ident: e_1_2_8_6_1
  doi: 10.1097/FTD.0b013e31823f3516
– ident: e_1_2_8_19_1
  doi: 10.1128/AAC.00626-12
– ident: e_1_2_8_27_1
  doi: 10.1016/S0149-2918(03)80126-1
– ident: e_1_2_8_24_1
  doi: 10.1128/AAC.01540-12
– ident: e_1_2_8_11_1
  doi: 10.1046/j.1365-2125.2003.01994.x
– ident: e_1_2_8_15_1
  doi: 10.1093/cid/cis437
– ident: e_1_2_8_4_1
– ident: e_1_2_8_13_1
– ident: e_1_2_8_22_1
  doi: 10.1128/AAC.01807-09
– ident: e_1_2_8_26_1
  doi: 10.1086/648679
– ident: e_1_2_8_28_1
  doi: 10.1002/jps.22109
– ident: e_1_2_8_7_1
  doi: 10.1093/jac/dkt369
– volume: 27
  start-page: 1141
  year: 2008
  ident: e_1_2_8_3_1
  article-title: Pharmacokinetic‐pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/s10096-008-0543-1
– ident: e_1_2_8_17_1
  doi: 10.1128/AAC.01083-10
– start-page: 1
  year: 2016
  ident: e_1_2_8_30_1
  article-title: Effects of cytochrome P450 3A4 and non‐genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes
  publication-title: Xenobiotica
– ident: e_1_2_8_23_1
  doi: 10.1093/jac/dks285
– ident: e_1_2_8_21_1
  doi: 10.1016/S1473-3099(15)70006-X
– ident: e_1_2_8_10_1
  doi: 10.1093/cid/cis599
SSID ssj0013165
Score 2.4147277
Snippet Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 197
SubjectTerms Administration, Intravenous
Administration, Oral
Adolescent
Age Factors
Antifungal Agents - pharmacokinetics
Antifungal Agents - therapeutic use
antifungals
Biological Variation, Population
Child
Child, Preschool
Chromatography, High Pressure Liquid - instrumentation
Chromatography, High Pressure Liquid - methods
Creatinine - blood
Dose-Response Relationship, Drug
Drug Monitoring - instrumentation
Drug Monitoring - methods
Female
high‐performance liquid chromatography
Humans
invasive fungal infections
Invasive Fungal Infections - blood
Invasive Fungal Infections - therapy
Male
Mass Spectrometry - instrumentation
Mass Spectrometry - methods
Sex Factors
Short Report
therapeutic drug monitoring
triazoles
Voriconazole - pharmacokinetics
Voriconazole - therapeutic use
Title Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.13401
https://www.ncbi.nlm.nih.gov/pubmed/28805964
https://www.proquest.com/docview/1928782645
https://pubmed.ncbi.nlm.nih.gov/PMC5736853
Volume 84
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9Kn_qi1s-zWqJI8aF7XG43uwl9qsVSFeWQFvogLPmsh-deuY9i-9d3Jnu7d2cVxLdAZpd8zGR-SSa_AXhTyLznPbeJ8z2TZNKizXGXJ1aK3CDctjKSVX_-kp-cZR_PxfkGHDRvYWp-iPbAjSwjrtdk4NpMV4zc2MsuT7P4dotitQgQfe0vbxB4TCNJkBg3W4IvWIUoiqf9ct0X3QGYd-MkV_FrdEDH9-Fb0_Q67uRHdz4zXXvzG6vjf_btAdxbAFN2WGvSNmz46iHsDWpm6-t9drp8qDXdZ3tssOS8vn4Ek5Vq5ibzC_YzLhZ0asjGgV0RFQmC_pvxyDPEyawNcGe6cgw7hdM90r-GU5IeVleawuoZel30YKyJGKuwxJrn54_h7Pj96dFJskjnkNhMcp5YozTl__N5wGU29ERwUkunjA5OCRGECYqjJ821FL1QUGL2QuJ2J3UEUhRPn8BmNa78M2CFk9aafpb6vsUNsFIiEC-dzJSxRapsB942E1vaBdc5pdwYlc2eB0e4jCPcgdet6GVN8PEnoVeNdpRofnSnois_nk9LBMgSQVaeiQ48rbWl_U0f10ah8qwDxZoetQJE7b1eUw2_R4pvUVBigBT7EdXk7y0r3x0NYuH5v4vuwBaOqKwPkl7A5mwy9y8RWs3MLtrQh0-70ZJuAVXqIyg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3JbhNBEC2FcIAL-2LWBkHEIWN5lp7pPnCAhMghiyzkSLkN08uAhRlHXgLON_Er_BNVPYttAhKXHLiN1KVRT3VV9aue6lcALxIRd6z1tWdsR3mR0Ohzvok9LXisEG5r4ciqDw7j7lH0_pgfr8GP-i5MyQ_RHLiRZ7h4TQ5OB9JLXq70SdsPMT-oSir37PwbJmyT17vbuLovg2DnXX-r61U9BTwdCd_3tJIZNaGzcY6-nnd4bkQmjFRZbiTnOVe59DGcx5ngnTyh7uCJQMwdGtoppR_iey_BZeogTkz92x-CxT8L3zWuJBCO6R33Kx4jqhtqprq6-52DtOcrM5cRs9vydq7Dz1pZZaXLl_Zsqtr67Dceyf9FmzfgWoW92ZvSWW7Cmi1uwUavJO-eb7L-4i7aZJNtsN6C1nt-G8ZLw8yMZ5_YVxcP6WCUjXJ2SmwrmNecjYaWYSrAmhp-lhWGoRbRoofZ98GEpAfFaUY3BxgCC9ykWV0UV-ATq2_Y34GjC9HHXVgvRoW9DywxQmsVRKENNOb4UvKcqPdEJJVOQqlb8Kq2pFRXdO7UVWSY1mkdrmjqVrQFzxvRk5LD5E9Cz2pzTDHC0G-jrLCj2STFHEAgjowj3oJ7pXk2rwkw_HMZRy1IVgy3ESD28tWRYvDZsZjzhHofhPgdzi7_PrP07VbPPTz4d9GncKXbP9hP93cP9x7CVdSuKM_NHsH6dDyzjxFJTtUT58AMPl60jf8CzgB9TQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VIiEuhfJqeBSDoOLQjfblXfvAARqilkIVoVbqbVm_ICJsojwK6V_ir_CjGHsfSShIXHrgtpJHK-94ZvyNd_wNwLOUJb7WgfSU9oUXM4k-F6jEk4wmAuG2ZI6s-v1Rsn8Svz2lp2vwo74LU_JDNAdu1jNcvLYOPlJmycmFHLWDCNODqqLyUM-_Yb42eXnQwcV9HobdN8d7-17VUsCTMQsCTwqe2x50OjHo6sanRrGcKS5yozilhgrDA4zmSc6ob1LbHDxlCLkjZTdKHkT43itwNU58bvtEdD6Ei18WgetbaTE4Znc0qGiMbNlQM9XVze8Cor1YmLkMmN2O170BP2tdlYUuX9qzqWjL899oJP8TZd6EjQp5k1elq2zCmi5uwU6vpO6e75LjxU20yS7ZIb0Fqff8NoyXhokazz6Rry4a2mNRMjTkzHKtYFZzPhxogokAaSr4SV4ogkpEex7k3_sTK90vznJ7b4AgrMAtmtQlcQU-kfp-_R04uRR93IX1YljoLSCpYlKKMI50KDHD55waS7zHYi5kGnHZghe1IWWyInO3PUUGWZ3U4YpmbkVb8LQRHZUMJn8SelJbY4bxxf40ygs9nE0yzAAYosgkpi24V1pn85oQgz_lSdyCdMVuGwHLXb46UvQ_Ow5zmtrOBxF-hzPLv88se73Xcw_3_130MVzrdbrZu4OjwwdwHZXLykOzh7A-Hc_0I4SRU7Ht3JfAx8s28V_Junv8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+drug+monitoring+of+voriconazole+for+treatment+and+prophylaxis+of+invasive+fungal+infection+in+children&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Allegra%2C+Sarah&rft.au=Fatiguso%2C+Giovanna&rft.au=De+Francia%2C+Silvia&rft.au=Favata%2C+Fabio&rft.date=2018-01-01&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=84&rft.issue=1&rft.spage=197&rft.epage=203&rft_id=info:doi/10.1111%2Fbcp.13401&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bcp_13401
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon